NEW YORK, Nov. 20, 2014 /PRNewswire/ --
About Epilepsy
Epilepsy is defined as a spectrum of brain disorders varying from benign symptoms to severe, disabling, and life-threatening symptoms. It can be caused by various factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and birth trauma. However, when the underlying cause of the disease is unidentified, as occurs in majority of the cases, it is known as idiopathic epilepsy. Epilepsy is characterized by repeated occurrence of generalized or focal seizures. Seizures result from an imbalance between the inhibitory and excitatory signals of the brain leading to sudden-onset of excitation. The occurrence of two or more unprovoked seizures is an important criteria to diagnose a person with seizures as being epileptic.
TechNavio's analysts forecast the Global Epilepsy market to grow at a CAGR of 5.06 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Epilepsy market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of anti-epileptic drugs approved for the treatment of symptoms of epilepsy. TechNavio's report, Global Epilepsy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Epilepsy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
Americas APAC EMEA
Key Vendors
GlaxoSmithKline Pfizer UCB
See the rest here:
Global Epilepsy Market 2014-2018